X

Trial Profile

A Phase 1 basket trial of VIR-5525 in patients with solid tumor

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SAR 446368 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Vir Biotechnology

Most Recent Events

06 Nov 2024 New trial record
31 Oct 2024 According to a Vir Biotechnology media release, company a cleared Investigational New Drug Application (IND) from the U.S. FDA. for VIR-5525 is a dual-masked EGFR targeted T-cell engager. Company plans to initiate a Phase 1 basket study of VIR-5525 in the first quarter of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com